Intellectual Property

This report examines the role played by IPRs in both upstream and downstream phases of the research, development and commercialization of biotechnology products and provides a review and analysis of the existing body of knowledge concerning the role of IPRs.

Hans Sauer tells us why the 2012 BIO International Convention is a can't-miss event if you are interested in issues concerning intellectual property, tech transfer and related topics.

The U.S. Supreme Court issued a favorable decision in the critical case of Microsoft v. i4i, in which Microsoft challenged the “clear and convincing evidence” standard traditionally used by courts in determining whether to invalidate an issued U.S. patent.

BIO will be co-hosting an event with the United States Patent and Trademark Office (USPTO) to celebrate the 30th anniversary of the issuance of U.S. patent 4,259,444 to Ananda Chakrabarty following the Supreme Court case, Diamond v. Chakrabarty, which held that Chakrabarty’s bioengineered bacterium was eligible for patenting.

The Patent Reform Act of 2011 would strengthen and improve our nation’s patent system, spurring innovation and job creation.

Brenda Herschbach Jarrell and Jennifer Groves present an overview of the IP landscape in China, India, Brazil and Korea.

A new federal recommendation could hinder innovations from biotechnology R&D by limiting gene patents and licenses.